Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
  • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
  • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
  • A61K31/727—Heparin; Heparan
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to heparins having at least one covalent bond with biotin or a derivative of biotin, as well as their method of preparation, pharmaceutical compositions containing them and their use in therapy.
• Heparin is a mixture of sulfated mucopolysaccharides of animal origin with a molecular weight of around 15,000 Dalton (Da). Heparin or heparins will be discussed in the following: the structures, average molecular masses and polydispersity of the heparin polysaccharide chains may indeed vary according to the animal species and the organ of origin of the heparin (examples heparin from pork mucus, beef intestine, etc.).
• Heparin catalyzes, particularly via antithrombin III (ATIII), the inhibition of two enzymes involved in the blood coagulation cascade, namely factor Xa and factor Ma (or thrombin). It is thus used therapeutically for its anticoagulant and anti-thrombotic properties. Heparin, however, has drawbacks that limit the conditions of its use. In particular, its important anticoagulant activity (in particular its high anti-factor IIa activity) can cause haemorrhages (Seminars in Thrombosis and Hemostasis, Vol 5, sup 3, 1999). Heparins are known for these unwanted hemorrhagic side effects.
• ATIII antithrombin III
• the goal is to restore or maintain the fluidity of the blood while avoiding causing haemorrhage. It is well known that, for any accidental cause, hemorrhage may occur in a patient undergoing treatment. It may also be necessary to intervene surgically in a patient under anti-thrombotic treatment.
• anticoagulants can be used in high doses to prevent blood clotting, and it is desirable to neutralize them at the end of the procedure. The need is therefore felt to have neutralizing antithrombotic agents to stop the anticoagulant activity at any time.
• Neutralizable antithrombotic agents such as biotinylated synthetic polysaccharides
• Their synthesis including in particular the grafting of biotin or the biotin derivative carried out on protected equivalents of the polysaccharides mentioned above and not on these polysaccharides themselves, is not applicable to the compounds of the present invention. Indeed, it is desired to carry out the biotinylation on finished products, which are mixtures of polysaccharides and are therefore heterogeneous products, on which the biotin grafting as described in the aforementioned patent applications would not make it possible to induce a regrowth. sufficient selectivity of the grafting position and would not allow the biotinylation of all functionalizable polysaccharide chains of heparins.
• the latter largely comprise polysaccharide chains which possess at their reducing end a degraded glycoserine, which can not be functionalized with biotin according to the protocol described by Osmond et al.
• the operating conditions described in this publication for the biotinylation of porcine heparin do not make it possible to obtain a complete and reproducible manner of biotinylated heparins with expected characteristics, such as a biotinylation rate sufficient to allow effective neutralization.
• the Applicant therefore aims to provide new neutralizable heparins by avidin or streptavidin and have biological properties comparable to native heparins.
• the present invention relates to novel modified heparins, hereinafter called “biotinylated heparins”, characterized in that the constituent polysaccharides of said heparins have at their reducing end a covalent bond with a group - (R 1) r Biot and meet the general formula (I):
• i is equal to 0 or 1
• R1 represents a sequence of formula (a) or (b):
• j and k which may be identical or different, are integers which can take any value from 1 to 10
• - Biot represents a biotin group or a biotin derivative
• n an integer having an average value of the order of 25 for a heparin with an average molecular mass of 15,000 Da
• X represents H or SO 3 Na
• Y represents COCH 3 or SO 3 Na
• the wavy line denotes a bond situated either below or above the plane of the pyranosic ring to which it is attached, as well as their pharmaceutically acceptable salts.
• biotin or a biotin derivative at the reducing end of the polysaccharide chains does not modify the pharmacological activity of the heparins.
• novel biotinylated heparins, object of the invention have anti-thrombotic activities comparable to native heparins, that is to say before biotinylation.
• Biot is a radical derived from hexahydro-2-oxo-1H-thieno [3,4-d] imidazole-4-pentanoic acid.
• the Biot group in the general formula (I) according to the invention corresponds to formula (c):
• biotin derivatives are commercially available ("Pierce” Biotin-avidin products catalog, 2005, pp. 7-11) or can be prepared using conventional methods known to those skilled in the art. Mention may in particular be made of the biotin derivatives mentioned in the patent application WO 02/24754.
• the index i may be equal to 0, in which case the binding with the biotin or the biotin derivative is carried out directly on the amine function carried by the saccharide unit at the level of the reducing end of the polysaccharide chains.
• i may be equal to 1 and the bond with the biotin or biotin derivative group may consist, for example, of a sequence of formula (a) above in which j is equal to 5, or a sequence of formula (b ) in which j and k are identical and are equal to 5.
• R1 may for example represent a sequence of formula -CO- (CH 2 ) 5 -NH or - CO- (CH 2 ) 5 -NH-CO- (CH 2 ) 5 -NH-.
• reducing end is understood to mean the end of the polysaccharide chain in which glucosamine or terminal mannosamine (mannosamine resulting from an epimerization in a basic medium of glucosamine) has a hemi-functional function.
• cyclic acetal corresponding to formula (II) below:
• X represents H or SO 3 Na
• Y represents COCH 3 or SO 3 Na
• the wavy line denotes a bond located either below or above the plane of the pyranosic ring to which it is attached (below: glucosamine, above: mannosamine) .
• polysaccharides constitutive of heparin means polysaccharides characterized by the repetition of a disaccharide unit containing a uronic acid residue (D-glucuronic acid or L-iduronic acid) and a D-glucosamine, which can be N-sulfated or N-acetylated.
• the disaccharide unit may also be O-sulfated at the C6 and / or C3 positions of D-glucosamine and at the C2 position of uronic acid (Heparin-binding proteins, H. Edward Conrad, 1998, p.1).
• heparin is a mixture of sulfated mucopolysaccharides of animal origin.
• Native heparins ie starting heparins before biotinylation, are referred to as "heparins".
• the heparins used in the present invention may especially be of bovine, ovine or porcine origin; more specifically, they may be derived from the lungs of oxen, intestinal mucosa of beef, intestinal mucous membranes of pigs or intestinal lining of sheep.
• the heparins used in the present invention are of porcine origin, for example derived from intestinal pig mucosa.
• biotinylated heparins according to the present invention are such that at least 60%, advantageously at least 64%, of the constituent polysaccharides of said heparins have at their reducing end a covalent bond with a group - (R 1) r Biot and correspond to the formula (I ) as defined above, and whatever the original structure of heparin; advantageously, at least 80% of the constituent polysaccharides of said heparins have at their reducing end a covalent bond with a - (R 1) -Biot group.
• the invention encompasses biotinylated heparins in the form of any of their pharmaceutically acceptable salts.
• the subject of the present invention is also a process for the preparation of the biotinylated heparins mentioned above, characterized in that: a) the heparin is treated with heparinase 3, b) and then a reductive amination is carried out on the product obtained previously in the presence of an amine salt and a reducing agent, at a temperature between 20 and 80 ° C. 1 c) finally acylation is carried out with a - (R 1) - group, activated Biot, where R 1, i and Biot are as defined in relation to formula (I) above, in the presence of a base in an aqueous medium or in an organic medium.
• the steps of the above preparation process can be controlled by an analytical HPLC monitoring, in particular of the SAX type, and more particularly of the CTA-SAX type, after depolymerization of the constituents of the heparin-derived mixture in the presence of a mixture of heparinases 1, 2 and 3.
• analytical monitoring may for example be carried out using the method described in the patent application US2005 / 0186679 A1.
• the overall yield of the process for preparing the biotinylated heparins according to the invention is therefore at least 60%, advantageously at least 64%.
• this yield is at least 80%.
• heparinase 1 the enzyme heparin lyase I (EC 4.2.2.7) of Flavobacterium heparinum,
• heparinase 2 the heparin lyase II enzyme of Flavobacterium heparinum
• heparinase 3 the heparin lyase III enzyme (EC 4.2.2.8) of Flavobacterium heparinum.
• Heparinase 3 makes it possible to eliminate the protein binding zone (glycoserine) in the heparin polysaccharide chains and to obtain chains whose reducing ends are free of glycoserine residues.
• Heparinases 1 and 2 allow the cleavage of polysaccharide chains into low molecular weight fragments (heparin depolymerization reactions).
• heparins of origin heparins prepared as previously reported in the literature. Reference is made in particular to the book "Heparin, manufacture, structure, properties, analyzes", JP Duclos, Ed. Masson, 1984. Heparins may in particular be prepared according to the process described in patent application US 2005/0215519. A1.
• the amine salt may be a quaternary amine salt; it is advantageously an ammonium halide salt having the formula NH 4 Z, where Z represents a halogen atom, such as a chlorine, fluorine, bromine or iodine atom.
• the reducing agent may be a borohydride salt, for example a cyanohydride salt.
• the temperature is advantageously between 50 and 80 ° C.
• the base may be a carbonate or hydrogencarbonate salt, especially in the form of a sodium or potassium salt, or any other water-soluble or soluble organic base. in an organic medium known to those skilled in the art.
• organic medium is understood to mean, for example, dichloromethane or dimethylformamide.
• the process for preparing the biotinylated heparins advantageously comprises the following steps: a) heparin is treated with heparinase 3, b) and then reductive amination is carried out on the product obtained previously in the presence of a sodium salt; ammonium halide and a borohydride salt, at a temperature between 50 and 80 0 C, c) finally acylation with a - (R1) - Biot group as defined previously in the form of activated ester, in the presence of a base in an aqueous medium.
• Biotinylated - (R1) - Biot derivatives as defined above can be involved in the acylation reaction directly in the form of activated esters, preformed or generated in situ using conventional coupling conditions known from the Man of the art.
• activated esters in the form of N-hydroxy-succinimide derivatives or of 3-sulfo-N-hydroxy-succinimide derivatives.
• heparin is treated with heparinase 3 to remove the remaining protein binding (i.e., native or degraded glycoserines) to obtain a compound 1 having a glycoserine residue-free reducing end.
• This heparin (compound 1) can then be subjected to a reductive amination to provide compound 2, having a free amine function at the reducing end, in the presence of an amine salt and a reducing agent such as a borohydride salt.
• This compound can then be acylated to provide the biotinylated compound 3, by reaction with an activated derivative of biotin - (R 1) r Biot, as defined above, in the presence of a base.
• Scheme 1 it is understood that compounds 1, 2 and 3 are a theoretical representation since they are actually, as
• Heparin EPB heparin marketed by Bioibérica
• HPLC "High Performance Liquid Chromatography"
• SAX "Strong anion exchange chromatography”
• CTA “Cetyl Trimethyl Ammonium”
• Sulfo-NHS sodium salt of the 3-sulfosuccinimidyl ester
• Heparinase 1 heparin lyase I enzyme (EC 4.2.2.7) from Flavobacterium heparinum;
• Heparinase 2 heparin lyase II enzyme of Flavobacterium heparinum
• Heparinase 3 heparin lyase III enzyme (EC 4.2.2.8) of Flavobacterium heparinum.
• the product can be controlled by depolymerization using a mixture of heparinases 1, 2 and 3 and analyzed by HPLC-SAX using the method described in US2005 / 0186679 A1. The results show a disappearance of at least 80% of the glycoserine species present in the starting heparin.
• heparin purified by heparinase 3 0.5 g are dissolved in a 5 M aqueous ammonium chloride solution. 0.5 g of sodium cyanoborohydride are added to the heparin solution. The mixture is heated at 70 ° C. for 24 hours.
• Heparin depolymerized with heparinase 3, amino-reduced and biotinylated At a temperature in the region of 20 ° C., 200 mg of amino-reduced depolymerized heparin are dissolved in 2 ml of 0.5M sodium hydrogen carbonate solution. 37 mg of Sulfo-NHS-LC-Biotin are added to the solution obtained. The solution obtained is stirred at a temperature close to 20 ° C. for 1 hour. The solution is diluted with 4 ml of 0.5M sodium hydrogen carbonate solution. 37 mg of Sulfo-NHS-LC-Biotin are added and the mixture is stirred for 2 hours.
• the product can be controlled by depolymerization using a mixture of heparinases 1, 2 and 3 and analyzed by HPLC-SAX using the method described in US patent application 2005/0186679 A1.
• the results show a at least 80% disappearance of the glycoserine species present in the starting heparin.
• heparin according to US 2005/0215519 A1 depolymerized by heparinase 3 and amino-reduced 0.5 g of heparin according to LJS 2005/0215519 A1 treated with heparinase 3 are dissolved in 20 ml of a 5 M aqueous solution of ammonium chloride. 0.5 g of sodium cyanoborohydride are added to the heparin solution. The mixture is heated at 70 ° C. for 24 hours. The solution is brought to a temperature close to 20 0 C, diluted with water (QSP 50 ml), then desalted on a column of Sephadex G10. The harvested fraction is lyophilized. 446 mg of a white lyophilisate are obtained. The yield observed is 89%. The product is engaged as in the next acylation step.
• Heparin according to US 2005/0215519 A1 depolymerized with heparinase 3, amino-reduced and biotinylated At a temperature in the region of 20 ° C., 200 mg of amino-reduced depolymerized heparin are dissolved in 2 ml of 0.5 M solution. of sodium hydrogencarbonate. 37 mg of Sulfo-NHS-LC-Biotin are added to the solution obtained. The solution is stirred at a temperature close to 20 ° C for 1 hour. The suspension obtained is diluted with 4 ml of 0.5M sodium hydrogen carbonate solution. 37 mg of Sulfo-NHS-LC-Biotin are added and the mixture is stirred for 2 hours.
• the product can be controlled by depolymerization using a mixture of heparinases 1, 2 and 3 and analyzed by HPLC-SAX using the method described in US patent application 2005/0186679 A1.
• the compounds according to the invention have been the subject of biochemical and pharmacological studies.
• anti-factor IIa activity and the anti-factor Xa (anti-FXa) activity in human plasma or a buffer system are analyzed by chromogenic method: the anti-factor IIa activity is tested by means of of anti-factor IIa activity of heparin Actichrome kit (American Diagnostica) containing the chromogenic substrate S-2238, the ⁇ -thrombin and I 1 human ATIII (antithrombin III).
• the anti-FXa activity is determined with the automated instrument of coagulation ACL 7000 (Instrumentation Laboratory) using the Heparin kit (Instrumentationation
• 10 ⁇ l of sample or international standards of low molecular weight heparins are diluted 1: 16 with Pantithrombin in human plasma or the buffer system containing 0.05 M Tris HCl, NaCl 0.154M, pH 7.4. 10 ⁇ l of this solution are added to a 96-well microtiter plate. The measurement is reproduced in triplicate (on 3 wells). The microtiter plate is maintained at 37 ° C. with stirring at 300 rpm. 40 ⁇ l of thrombin are added to each of the wells and incubated for exactly 2 minutes. 40 ⁇ l of Spectrozyme are added. After 90 seconds, the reaction is stopped by adding 40 ⁇ l of acetic acid. Absorption is measured at 405 nm using a SpectraMax 340 (Molecular devices).
• the sample or international standards of low molecular weight heparins are diluted in human plasma or buffer system containing 0.05 M Tris HCl, 0.154 M NaCl, pH 7.4.
• the samples containing the heparinoids in plasma or buffer were further diluted 1:20 with a working buffer containing I 1 ATIII, and placed in duplicate in the sample rotor.
• the factor Xa reagent and the chromogenic substrate are poured into the indicated reservoirs of the automated ACL 7000 coagulation instrument.
• the measurement of the anti-FXa activity is carried out with the "heparin" protocol integrated in the ACL 7000 software.
• 50 ⁇ l of the sample (diluted with the working buffer) are mixed with 50 ⁇ l. ⁇ l of factor Xa reagent.
• 50 ⁇ l of chromogenic substrate with a concentration of 1.1 mM are added and the changes in absorption as a function of time are measured at the wavelength of 405 nM.
• Biotinylated heparins according to the present invention can be used for the preparation of medicaments. They can especially be used as anti-thrombotic drugs.
• the subject of the invention is medicaments which comprise a biotinylated heparin as defined above.
• These medicaments find use in therapeutics, in particular in the treatment and prevention of venous thromboses, arterial thrombotic accidents, particularly in the case of myocardial infarction or unstable angina, peripheral arterial thromboses, such as osteoarthritis of the arteries. lower limbs, cerebral arterial thromboses and strokes. They are also useful in the prevention and treatment of smooth muscle cell proliferation, angiogenesis, and as neuroprotective agents of atherosclerosis and arteriosclerosis.
• the present invention also relates to a method of treatment of the aforementioned pathologies which comprises the administration to a patient of an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts.
• a method of treatment of the aforementioned pathologies which comprises the administration to a patient of an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts.
• the subject of the present invention is a pharmaceutical composition
• a pharmaceutical composition comprising, as active ingredient, a biotinylated heparin according to the invention or a pharmaceutically acceptable salt thereof, as well as at least one pharmaceutically acceptable inert excipient .
• excipients are chosen according to the desired pharmaceutical form and mode of administration, for example the oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, transmucosal, local or rectal route.
• each dosage unit the active ingredient is present in the amounts adapted to the daily doses envisaged in order to obtain the desired prophylactic or therapeutic effect.
• Each dosage unit may contain from 25 to 150 mg of active ingredient, advantageously from 30 to 100 mg.
• These doses of anticoagulant compounds may be neutralized by avidin or streptavidin. There may be special cases where higher or lower dosages are appropriate; such dosages are not outside the scope of the invention. According to the usual practice, the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.
• the compounds according to the invention may also be used in combination with one or more other active ingredients useful for the desired therapy, such as antithrombotics, anticoagulants or antiplatelet agents.
• the subject of the present invention is also a method employing avidin or streptavidin, characterized in that it makes it possible to neutralize the biotinylated heparins according to the invention.
• avidin or streptavidin may be used for the preparation of medicaments for neutralizing biotinylated heparins according to the present invention.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Polymers & Plastics (AREA)
• Materials Engineering (AREA)
• Biochemistry (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Dermatology (AREA)
• Cardiology (AREA)
• Diabetes (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Heart & Thoracic Surgery (AREA)
• Psychiatry (AREA)
• Urology & Nephrology (AREA)
• Toxicology (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38470146

Family Applications (1)

Country Status (15)

Families Citing this family (5)

Family Cites Families (1)

• 2007
  • 2007-02-14 FR FR0701053A patent/FR2912408A1/fr not_active Withdrawn
• 2008
  • 2008-02-04 TW TW097104306A patent/TW200902036A/zh unknown
  • 2008-02-12 CN CNA2008800048677A patent/CN101605549A/zh active Pending
  • 2008-02-12 RU RU2009134160/15A patent/RU2009134160A/ru not_active Application Discontinuation
  • 2008-02-12 AU AU2008228161A patent/AU2008228161A1/en not_active Abandoned
  • 2008-02-12 EP EP08761872A patent/EP2120970A1/fr not_active Withdrawn
  • 2008-02-12 CA CA002678166A patent/CA2678166A1/fr not_active Abandoned
  • 2008-02-12 JP JP2009549840A patent/JP2010518251A/ja not_active Withdrawn
  • 2008-02-12 BR BRPI0808070-4A patent/BRPI0808070A2/pt not_active IP Right Cessation
  • 2008-02-12 KR KR1020097016909A patent/KR20090109105A/ko not_active Application Discontinuation
  • 2008-02-12 MX MX2009008025A patent/MX2009008025A/es not_active Application Discontinuation
  • 2008-02-12 WO PCT/FR2008/000172 patent/WO2008113918A1/fr active Application Filing
  • 2008-02-13 AR ARP080100610A patent/AR065328A1/es unknown
• 2009
  • 2009-07-15 IL IL199880A patent/IL199880A0/en unknown
  • 2009-08-11 US US12/539,237 patent/US20100075922A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events